In a follow-up to its September report on 27 deaths associated with the C.R. Bard “Recovery” IVC blood clot filter, NBC News reports that Bard knew that its G2 Series IVC filters — intended to replace the company’s Recovery filter — also “had similar and potentially fatal flaws soon after it was put on the market.” NBC obtained internal Bard records showing that Bard was concerned about reported failures of the G2 Series filters just four months after they were approved by the FDA.… Read More


NBC News has released the results of a year-long investigation into medical device manufacturer C.R. Bard and their “Recovery” blood clot filter.  Part 1 of their report details the defects in the product; perhaps more shocking, Part 2 of their report asserts that C.R. Bard may have submitted the forged signature of a prominent regulatory… Read More


Posted by Marilyn McGoldrick on Feb 24, 2015 12:12:07 PM   Mesh manufacturer C.R. Bard is reportedly in talks to settle the thousands of pelvic mesh lawsuits pending against it in federal and state courts across the country. At the urging of federal judge Joseph R. Goodwin, C.R. Bard’s attorneys and plaintiffs’ lead counsel have been… Read More


Posted by Marilyn McGoldrick on Jan 14, 2015 12:29:03 PM   The federal judge overseeing all transvaginal mesh litigation has denied C.R. Bard’s motion to delay bellwether trials, also known as test trials, scheduled for next month. C.R. Bard, a defendant in more than 12,000 cases brought by women who received defective Avaulta pelvic mesh… Read More


Posted by Marilyn McGoldrick on Dec 1, 2014 12:32:05 PM   A jury in West Virginia has awarded $18.5 million to four women who suffered painful complications after receiving Boston Scientific’s Obtryx vaginal mesh slings. The verdict included an award of $4 million in punitive damages, $1 million to each plaintiff to punish for Boston Scientific’s… Read More


Posted by Marilyn McGoldrick on Oct 9, 2014 8:46:00 AM   Transvaginal mesh manufacturer C.R. Bard reportedly will settle over 500 of its pending vaginal mesh lawsuits for over $21 million dollars, according to Bloomberg News, which cited anonymous sources “familiar with the accords”. C.R. Bard is a defendant in more than 12,000 lawsuits in… Read More


More medical evidence of the long-term consequences of the use of transvaginal mesh was presented during the American Urological Association’s annual meeting this month. While several studies showed that the majority of women who undergo surgery to alleviate pain from transvaginal mesh implants are pain free after excision surgery, there is still a significant percentage of women whose pain continues after surgical removal of the mesh.… Read More


C.R. Bard recently settled the second federal Avaulta transvaginal mesh bellwether case just before trial which was scheduled to start last week. The settlement terms between Bard and the plaintiff, a North Carolina woman named Wanda Queen, are undisclosed. The announcement was made by U.S. District Court Judge Joseph R. Goodwin, who presides over all six surgical mesh consolidated federal multi-district litigation (MDL) dockets. Besides the Bard consolidated cases, Judge Goodwin presides over litigation involving American Medical Systems, Inc., Boston Scientific Corp., Coloplast Corp., Cook Medical, Inc., and Ethicon, Inc.… Read More


On August 15, 2013, a West Virginia jury awarded Donna Cisson a $2 million verdict, $250,000 in compensatory damages and $1.75 million in punitive damages, against C. R. Bard for injuries caused by its transvaginal mesh implant Avaulta. Donna Cisson’s attorneys presented evidence that her vaginal mesh implant caused bleeding, constant intractable pain and bladder spasms. Ultimately Cisson endured several surgeries to remove much of the surgical mesh; she still has 22 inches of mesh inside her body and the constant pain.… Read More


Posted by Marilyn McGoldrick on Jul 1, 2013 4:06:00 PM Newly-unsealed confidential records show that C.R. Bard, Inc., knowingly ignored a part supplier’s direct warning that the plastic Bard was supplied with was unsuitable for human implantation. The revelation about Bard’s behavior comes as the surgical mesh manufacturer is embroiled in litigation over its defective… Read More